Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Provexis, which focuses on the discovery, development and licensing of scientifically-proven functional food, medical food and dietary supplement technologies, has completed human trial comparing the effects of its Fruitflow anti-thrombotic technology with aspirin.
Subscribe to our email newsletter
Fruitflow is a patented tomato extract which inhibits several pathways involved in platelet aggregation.
Provexis said that the trial was undertaken at the Rowett Institute of Nutrition and Health, part of the University of Aberdeen, with independent statistical analysis by Bioss, and is the tenth placebo controlled human trial undertaken with the Fruitflow extract.
The trial compared the effects of Fruitflow and aspirin over a five hour time course. Interactions between Fruitflow and aspirin when consumed together were also studied. 43 healthy subjects completed the trial over a 7-month period and the results are positive.
Fruitflow showed up to 30% reduction from baseline platelet aggregation in each of three different biological pathways, while a single dose of aspirin caused up to 60% reduction in a single pathway, with lesser effects on the other two. The broader antiplatelet effect of Fruitflow reflects the company’s aim to provide a daily dietary supplement with a significant effect on blood flow, but without suppressing platelet aggregation completely.
The study also showed no negative interactions between Fruitflow and aspirin when consumed together.
The company said that the findings are prominent and serve to demonstrate the potential effectiveness of Fruitflow as a preventative measure in cardiovascular health through inhibiting platelet aggregation, with no side effects. This trial is an important milestone for the Company as it has worked to develop and patent the technology worldwide while submitting Fruitflow to rigorous scientific and regulatory testing to substantiate efficacy and safety.
Stephen Moon, CEO of Provexis, said: “We are delighted with the results of this latest human trial, which highlight the substantial effect that Fruitflow can have on platelet aggregation, without the associated side effects known to occur with aspirin.
“On 12th February we announced intent to enter into an agreement with DSM Nutritional Products, the world’s leading supplier of vitamins, carotenoids and other fine chemicals to the feed, food, pharmaceutical and personal care industries. Today’s news provides further strength to the commercialisation plans for Fruitflow and in the planned alliance we anticipate developing multiple routes to market.”